论文部分内容阅读
依那普利(Enalapril,Mk-421)是1980年由美国Merck公司推出的第二代口服无巯基的血管紧张素转换酶抑制剂(ACEI),经过临床与动物实验证实在抗高血压和充血性心力衰竭等方面有较好的疗效.目前在国内外已广泛应用于临床,本文旨在对原发性高血压(EH)患者顿服依那普利后,观察血清药物浓度及降压作用与血浆血管紧张素Ⅱ(AⅡ)、内皮素(ET)和心钠素(ANF)之间的变化关系.
Enalapril (Mk-421) is the second generation of oral thiol-free angiotensin-converting enzyme inhibitor (ACEI) introduced by Merck in 1980. It has been proved in clinical and animal experiments that antihypertensive and hyperemic Sexual heart failure, etc. There are currently at home and abroad have been widely used in clinical, this article aims to patients with essential hypertension (EH) Dayton enalapril, observe the serum drug concentration and antihypertensive effect And plasma angiotensin Ⅱ (A Ⅱ), endothelin (ET) and atrial natriuretic peptide (ANF).